{"filing":{"accession_number":"0001104659-26-078453","cik":"0001583107","ticker":"TBPH","company_name":"Theravance Biopharma, Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"tm2619064d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926078453/tm2619064d1_8k.htm"},"events":[{"id":14419,"run_id":12840,"accession_number":"0001104659-26-078453","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"Theravance Biopharma entered into a definitive Agreement and Plan of Merger with Zymeworks Inc. on June 28, 2026, whereby Zymeworks will acquire Theravance for $17.00 per share in cash plus contingent value rights, representing approximately $929 million in equity value. The transaction is subject to shareholder approval and customary closing conditions, with expected close in the second half of 2026.","company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":11844,"accession_number":"0001104659-26-078453","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Theravance Biopharma entered into a definitive Agreement and Plan of Merger with Zymeworks Inc. on June 28, 2026, providing for the acquisition of Theravance at $17.00 per share in cash plus contingent value rights. This represents a material acquisition transaction with an equity value of approximately $929 million, subject to shareholder approval and customary closing conditions, with expected close in the second half of 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:31:51.089702+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11845,"accession_number":"0001104659-26-078453","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Theravance Biopharma entered into a definitive agreement to be acquired by Zymeworks for $17.00 per share in cash plus a contingent value right, representing approximately $929 million in equity value. This is a material acquisition transaction that fundamentally changes the company's status and requires shareholder approval. The Item 7.01 disclosure furnishes supplemental employee communications regarding the merger, which is the principal event disclosed.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:31:51.089702+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11846,"accession_number":"0001104659-26-078453","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"The filing discloses entry into a definitive merger agreement whereby Zymeworks will acquire Theravance Biopharma for $17.00 per share in cash (approximately $929 million equity value) plus a contingent value right. This is a material acquisition transaction requiring shareholder approval and expected to close in the second half of 2026. The press release explicitly states \"Theravance Biopharma enters into definitive agreement to be acquired by Zymeworks,\" making this a clear ma_activity event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:31:51.089702+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11844,"accession_number":"0001104659-26-078453","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Theravance Biopharma entered into a definitive Agreement and Plan of Merger with Zymeworks Inc. on June 28, 2026, providing for the acquisition of Theravance at $17.00 per share in cash plus contingent value rights. This represents a material acquisition transaction with an equity value of approximately $929 million, subject to shareholder approval and customary closing conditions, with expected close in the second half of 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:31:51.089702+00:00","company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","filing_date":"2026-06-29"},{"id":11845,"accession_number":"0001104659-26-078453","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Theravance Biopharma entered into a definitive agreement to be acquired by Zymeworks for $17.00 per share in cash plus a contingent value right, representing approximately $929 million in equity value. This is a material acquisition transaction that fundamentally changes the company's status and requires shareholder approval. The Item 7.01 disclosure furnishes supplemental employee communications regarding the merger, which is the principal event disclosed.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:31:51.089702+00:00","company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","filing_date":"2026-06-29"},{"id":11846,"accession_number":"0001104659-26-078453","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"The filing discloses entry into a definitive merger agreement whereby Zymeworks will acquire Theravance Biopharma for $17.00 per share in cash (approximately $929 million equity value) plus a contingent value right. This is a material acquisition transaction requiring shareholder approval and expected to close in the second half of 2026. The press release explicitly states \"Theravance Biopharma enters into definitive agreement to be acquired by Zymeworks,\" making this a clear ma_activity event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:31:51.089702+00:00","company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","filing_date":"2026-06-29"}]}